Bolt Biotherapeutics, Inc. Logo

Bolt Biotherapeutics, Inc.

Clinical-stage biotech developing immuno-oncology therapies using the innate immune system.

BOLT | US

Overview

Corporate Details

ISIN(s):
US0977021049
LEI:
Country:
United States of America
Address:
900 CHESAPEAKE DRIVE, 94063 REDWOOD CITY

Description

Bolt Biotherapeutics is a clinical-stage biotechnology company developing immuno-oncology therapies to treat cancer. The company's approach leverages the innate immune system, particularly myeloid cells, to create a therapeutic anti-tumor response. Its proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune-stimulating agents. This technology is designed to repolarize tumor-supportive immune cells, such as macrophages, into tumor-destructive ones, while also activating the adaptive immune system. The company's pipeline includes multiple candidates generated from the ISAC platform and other novel approaches. A key candidate, BDC-3042, is a first-in-class Dectin-2 agonist antibody being evaluated in clinical trials.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Bolt Biotherapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bolt Biotherapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bolt Biotherapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AVACTA GROUP PLC Logo
Clinical-stage biotech developing targeted oncology drugs with a proprietary platform.
United Kingdom
AVCT
AVADEL PHARMACEUTICALS PLC Logo
Biopharmaceutical company developing therapies for sleep disorders, focusing on narcolepsy.
United States of America
AVDL
Avalon GloboCare Corp. Logo
Develops cell-based immunotherapies and provides precision diagnostics and lab services.
United States of America
ALBT
Avidity Biosciences, Inc. Logo
Develops a class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs).
United States of America
RNA
Axogen, Inc. Logo
Develops and commercializes surgical solutions for peripheral nerve repair.
United States of America
AXGN
Axsome Therapeutics, Inc. Logo
A biopharmaceutical company developing therapies for central nervous system disorders.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
A specialty pharma company developing novel therapeutics for complex CNS diseases.
United States of America
AYTU
Azitra, Inc. Logo
Clinical-stage biopharma company developing microbiome-based therapies for skin diseases.
United States of America
AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland
BANB
Barinthus Biotherapeutics plc. Logo
Clinical-stage biopharma developing immunotherapies that guide T cells to control disease.
United States of America
BRNS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.